secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001493152-25-009384
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Biosciences to restate 2023 and quarterly 2023/2024 financials due to accrued royalty errors
--------------------------------------------------------------------------------

- Accrued royalties overstated by $5.3M to $7.1M across 2023 and 2024 quarterly balance sheets.
- Restatement expected to reduce liabilities and increase net income; revenues and cash flows unchanged.
- Non-reliance on financial statements for FY2023, Q1-Q3 2023 and Q1-Q3 2024.
- Management will report a material weakness in internal controls over accrued royalty assessment.
- Cumulative impact from 2015-2022 is $4.8M aggregate; no restatement for periods before 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315225009384/0001493152-25-009384-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315225009384/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-009384

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer